Biosimilars Market: Industry Analysis, Trend, Growth, Opportunity, Forecast 2022-2030
Global Biosimilars Market Forecast to 2030 released By Global Market Insights provides Market information about industry Top Key Players, Countries, Type and Application. This Biosimilars report also states Company Profile, sales, Biosimilars Market revenue and price, market share, market growth and gross margin by regions, Strategic recommendations for the new entrants, Market forecasts for a minimum of five years of all the mentioned segments, sub segments and the regional markets.
Recently, key players have been increasingly collaborating with competitors to enhance their business standing, which has improved overall market dynamics. For instance, in February 2022, Biocon Biologics Ltd. (BBL), a Biocon subsidiary, inked an agreement to acquire Viatris Inc.'s biosimilars business in a $3.35 billion deal.
Browse key industry insights spread across 650 pages with 1,202 tables & 19 figures and charts from the report, “Biosimilars Market Analysis By Product (Recombinant Non-Glycosylated Proteins {Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Interferon}, Recombinant Glycosylated Proteins {Erythropoietin, Monoclonal Antibodies, Follitropin, Low Molecular Weight Heparin}), Application (Hematology {Neutropenia, Anemia}, Oncology {Lung Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Leukemia or Blood Cancer}, Autoimmune Disease {Arthritis, Inflammatory Bowel Disease, Psoriasis}, Growth Hormone Deficiency, Diabetes), Manufacturer (Contract Research and Manufacturing Services, In-house), Technology (Recombinant DNA Technology, Monoclonal Antibodies Technology) Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2030” in detail along with Table of Contents:
https://www.gminsights.com/industry-analysis/biosimilars-market
With the acquisition, Biocon Biologics aimed to offer one of the sector's largest and most comprehensive portfolios of commercialized biosimilars with the addition of a variety of commercially available insulins, immunology & oncology biosimilars, and several other biosimilar assets.
The biosimilars market has been bifurcated in terms of product, application, manufacturer, technology, and region.
Based on product, the industry has been divided into recombinant glycosylated proteins and recombinant non-glycosylated proteins. The human growth hormone segment of the recombinant non-glycosylated proteins registered a substantial market valuation of around $2800 million and is slated to expand at a robust CAGR of approximately 15.4% over the review timeline owing to increased biosimilar demand globally.
With respect to application, the biosimilars market has been classified into hematology, oncology, autoimmune disease, growth hormone deficiency, diabetes, and others. The diabetes segment accounted for more than 14.2% of the application market share and is projected to exhibit a positive CAGR of nearly 15.2% over the forecast period attributed to surging prevalence of the disease among the global population.
With regards to manufacturer, the market has been categorized into contract research and manufacturing services and in-house. In 2021, the biosimilars market share from the contract research and manufacturing services segment was worth over $6,900 million and is set to showcase robust growth through 2030. The biosimilars industry's top players manufacture their products in the warehouses they own, which has resulted in the in-house category contributing to over three-fourths of the market size in 2021.
Based on technology, the biosimilars industry has been divided into recombinant DNA technology (rDNA technology) and monoclonal antibodies (MAb) technology. The MAb technology is the most recent and cutting-edge method of producing biosimilars, and as a result, it is foreseen to experience a CAGR of around 13.9% over the forthcoming years.
Partial Table of Contents (ToC) of the report:
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Biosimilars industry 3600 synopsis, 2017-2030 (USD Million)
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Application trends
2.1.4 Manufacturer trends
2.1.5 Technology trends
2.1.6 Regional trends
Browse complete table of content of this report @ https://www.gminsights.com/toc/detail/biosimilars-market
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.
Contact Us
Arun Hegde
Corporate Sales, USA
Global Market Insights Inc.
Phone: 1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com